B. Riley Wealth Advisors Inc. Sells 4,707 Shares of AstraZeneca PLC (NASDAQ:AZN)

B. Riley Wealth Advisors Inc. trimmed its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 25.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 13,620 shares of the company’s stock after selling 4,707 shares during the quarter. B. Riley Wealth Advisors Inc.’s holdings in AstraZeneca were worth $1,061,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the stock. McClarren Financial Advisors Inc. grew its position in shares of AstraZeneca by 320.8% during the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after buying an additional 247 shares in the last quarter. GHP Investment Advisors Inc. purchased a new position in AstraZeneca in the 2nd quarter worth $26,000. Capital Performance Advisors LLP acquired a new stake in shares of AstraZeneca in the third quarter worth $28,000. Ashton Thomas Securities LLC acquired a new stake in shares of AstraZeneca during the 3rd quarter worth approximately $45,000. Finally, Hollencrest Capital Management raised its holdings in AstraZeneca by 38.4% in the 3rd quarter. Hollencrest Capital Management now owns 692 shares of the company’s stock worth $54,000 after purchasing an additional 192 shares during the period. 20.35% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $89.75.

AstraZeneca Stock Performance

AZN opened at $67.18 on Wednesday. The stock’s 50 day simple moving average is $69.77 and its 200 day simple moving average is $76.57. The stock has a market cap of $208.30 billion, a P/E ratio of 32.14, a P/E/G ratio of 1.19 and a beta of 0.45. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $87.68. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The company had revenue of $13.57 billion during the quarter, compared to analysts’ expectations of $13.08 billion. During the same quarter in the previous year, the business posted $0.87 earnings per share. The firm’s quarterly revenue was up 18.0% compared to the same quarter last year. As a group, equities analysts anticipate that AstraZeneca PLC will post 4.11 EPS for the current fiscal year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.